With significant legislative, regulatory, and litigation developments at both the federal and state levels, as well as increasing scrutiny of PBM business practices, this program will provide timely insights for stakeholders.
This webinar will provide a comprehensive update on:
- Federal Policy Developments: The provisions of the leading PBM reform bill in Congress, implications of the President’s Most Favored Nation (MFN) drug pricing initiative and the evolving Direct-to-Consumer (DTC) landscape, and major regulatory proposals including potential revisions to bona fide service fee qualification standards and implementation of 340B rebate models and other duplicate discount mechanisms.
- State Law Updates: Key requirements of new state laws, and the status of litigation challenging them.
- Litigation Trends: Recent examples of litigation filed by the FTC, states, pharmacies, or putative classes against PBMs bringing allegations such as price fixing, including with respect to GoodRx’s “integrated savings program.”
With PBMs at the center of ongoing policy debates, regulatory reforms, and high-stakes litigation, this is a critical time to understand the risks and opportunities facing the industry. We look forward to your participation in this informative program.
